Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Antibodies, Monoclonal, Humanized

19 articoli — 1999-2026

RI Casi indimenticabili
Encefalopatia necrotizzante acuta da influenza B: il ruolo chiave della mutazione di RANBP2

Cavallo F.

2026/8 — pag. 526-526 — DOI

The paper describes the case of a 16-year-old girl with influenza B who progressively developed confusion and behavioural changes during observation. Prompt clinical suspicion led to the diagnosis of acute necrotising encephalopathy (ANE1), a rare co...

0*18 Pillole
Accesso libero
Teplizumab

2026/118 — pag. 8-8

RI Editoriali
Accesso libero
Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità

Marchetti F, Cocchi E.

2025/10 — pag. 619-620 — DOI

EL Ricerca
Accesso libero
Impatto preliminare della profilassi universale con nirsevimab in ambito neonatale: esperienza monocentrica di Bergamo

Colombo M, Ferrari S, Mangili G

2025/6 — pag. 131-137 — DOI

Respiratory Syncytial Virus (RSV) is the main cause of hospitalisation in infants. The present single-centre observational study aimed to analyse the adherence to universal prophylaxis with Nirsevimab and to evaluate its preliminary effectiveness in ...

RI Lettere
Accesso libero
Nirsevimab tra presente e immediato futuro

Fusco F, Sambugaro D, Marchetti F.

2025/5 — pag. 284-288 — DOI

0*18 Succede ai bambini
Accesso libero
La prima stagione del Nirsevimab in Italia

2024/111 — pag. 4-5

0*18 Appunti di pediatria
Accesso libero
VRS, VRS, VRS!

2024/109 — pag. 6-7

EL I Poster degli specializzandi
Accesso libero
Un caso di pericardite recidivante colchicina-resistente

Maggio MC, Alizzi C, Di Leto E, Ippolito A, Sferlazza F, Corsello G

2023/6 — pag. 111-112 — DOI

A 9-year-old boy affected by colchicine-resistant idiopathic pericarditis was successfully treated with an IL-1 receptor antagonist (anakinra)....

0*18 Pillole
Accesso libero
Emicizumab

2022/104 — pag. 8-8

0*18 Appunti di pediatria
Accesso libero
Eosinofili difficili… da mandare giù

2022/104 — pag. 6-7

RI Farmacoriflessioni
La profilassi dell’infezione da virus respiratorio sinciziale: dal palivizumab al nirsevimab

Servadio M, Belleudi V, Marchetti F, Addis A.

2022/10 — pag. 632-639 — DOI

The Respiratory Syncytial Virus (RSV) is considered the leading cause of lower respiratory tract infections (LRTI) in children aged < 2 years. In high-risk children, including preterm infants, or in children with bronchopulmonary dysplasia (BPD) and ...

RI Farmacoriflessioni
Il dupilumab nell’esofagite eosinofila: una nuova frontiera?

Mainetti M, Troisi A, Turlà G, Fontijn S, Rametta G, Buzzi A, Mussetto A, Marchetti F.

2022/9 — pag. 583-587 — DOI

Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated or antigen-mediated oe-sophageal disease. Therapeutic first-line options currently available for EoE are elimina-tion diets, proton pump inhibitors (PPIs) and steroids. The ultimate goal o...

0*18 Pillole
Accesso libero
Lanadelumab

2022/101 — pag. 10-10

RI Farmacoriflessioni
Tutto quello che il pediatra dovrebbe sapere sul mepolizumab

Prisco A, Carlone G, Maschio M, Badina L, Barbi E

2021/6 — pag. 374-378 — DOI

Mepolizumab, a monoclonal antibody blocking IL-5, is efficacious in the treatment of severe lung diseases sharing eosinophilic inflammation pattern. The paper describes two cases in which the drug was used with excellent results. The first involved a...

RI Focus
Rachitismo ipofosforemico X-linked

L. Lucchetti, D. Fintini, M. Cappa, F. Emma

2020/7 — pag. 430-436 — DOI

X-linked hypophosphatemia (XLH) is an X-linked disorder with dominant penetration, caused by mutations in the PHEX gene, which encodes for an endopeptidase that is predominantly expressed in osteoblasts, osteocytes and odontoblasts. PHEX mutations ...

RI Pagine elettroniche
Glomerulopatia da depositi di C3

S. Amoroso, M. Pennesi, A. Ventura

2018/2 — pag. 119-122

C3-glomerulopathy includes several nephropathy charac-terised by almost only C3 deposits without immunoglobu-lins with a mesangial proliferative or membrano-proliferative pattern on light microscopy. C3-glomerulopathy is determined by a dysregulation...

RI L'esperienza che insegna
Quando l’asma è “difficile”: il ruolo dell’omalizumab

G. Vieni, L. Biserna, F. Marchetti

2017/3 — pag. 177-181

The percentage of asthmatic children with severe asthma is low (< 5%). Children with severe asthma require treatment with high dose of inhaled steroids plus a second controller and/or systemic steroids to control symptoms. They can also remain unco...

EL Appunti di Terapia
Accesso libero
Il Natalizumab nel trattamento della malattia di Crohn

G. Bartolozzi

2006/1

RI Farmacologia clinica
Accesso libero
Palivizumab: un anticorpo monoclonale umanizzato contro il virus respiratorio sinciziale

L. De Seta, G. Orso

1999/8 — pag. 491-494

Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent the categories at highest risk of severe RSV infections. Paliv...